274 related articles for article (PubMed ID: 27797972)
1. Inhibition of
Odate S; Veschi V; Yan S; Lam N; Woessner R; Thiele CJ
Clin Cancer Res; 2017 Apr; 23(7):1771-1784. PubMed ID: 27797972
[No Abstract] [Full Text] [Related]
2. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
3. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D; Kurzrock R; Kim Y; Woessner R; Younes A; Nemunaitis J; Fowler N; Zhou T; Schmidt J; Jo M; Lee SJ; Yamashita M; Hughes SG; Fayad L; Piha-Paul S; Nadella MV; Mohseni M; Lawson D; Reimer C; Blakey DC; Xiao X; Hsu J; Revenko A; Monia BP; MacLeod AR
Sci Transl Med; 2015 Nov; 7(314):314ra185. PubMed ID: 26582900
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA nuclear-enriched abundant transcript 1 regulates proliferation and apoptosis of neuroblastoma cells treated by cisplatin by targeting miR-326 through Janus kinase/signal transducer and activator of transcription 3 pathway.
Yang B; Ye X; Wang J; Xia S
Neuroreport; 2020 Dec; 31(17):1189-1198. PubMed ID: 33044324
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
6. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.
Burkhart CA; Cheng AJ; Madafiglio J; Kavallaris M; Mili M; Marshall GM; Weiss WA; Khachigian LM; Norris MD; Haber M
J Natl Cancer Inst; 2003 Sep; 95(18):1394-403. PubMed ID: 13130115
[TBL] [Abstract][Full Text] [Related]
7. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Reilley MJ; McCoon P; Cook C; Lyne P; Kurzrock R; Kim Y; Woessner R; Younes A; Nemunaitis J; Fowler N; Curran M; Liu Q; Zhou T; Schmidt J; Jo M; Lee SJ; Yamashita M; Hughes SG; Fayad L; Piha-Paul S; Nadella MVP; Xiao X; Hsu J; Revenko A; Monia BP; MacLeod AR; Hong DS
J Immunother Cancer; 2018 Nov; 6(1):119. PubMed ID: 30446007
[TBL] [Abstract][Full Text] [Related]
8. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
Shastri A; Choudhary G; Teixeira M; Gordon-Mitchell S; Ramachandra N; Bernard L; Bhattacharyya S; Lopez R; Pradhan K; Giricz O; Ravipati G; Wong LF; Cole S; Bhagat TD; Feld J; Dhar Y; Bartenstein M; Thiruthuvanathan VJ; Wickrema A; Ye BH; Frank DA; Pellagatti A; Boultwood J; Zhou T; Kim Y; MacLeod AR; Epling-Burnette PK; Ye M; McCoon P; Woessner R; Steidl U; Will B; Verma A
J Clin Invest; 2018 Dec; 128(12):5479-5488. PubMed ID: 30252677
[TBL] [Abstract][Full Text] [Related]
9. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
10. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.
Borriello L; Nakata R; Sheard MA; Fernandez GE; Sposto R; Malvar J; Blavier L; Shimada H; Asgharzadeh S; Seeger RC; DeClerck YA
Cancer Res; 2017 Sep; 77(18):5142-5157. PubMed ID: 28687621
[TBL] [Abstract][Full Text] [Related]
12. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
14. STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
Njatcha C; Farooqui M; Kornberg A; Johnson DE; Grandis JR; Siegfried JM
Mol Cancer Ther; 2018 Sep; 17(9):1917-1926. PubMed ID: 29891486
[TBL] [Abstract][Full Text] [Related]
15. [Effects of STAT3 antisense oligonucleotide on proliferation and apoptosis of non-small cell lung cancer cell line A549].
Zhu BR; Cai JM; Tang GS; Li BL; Gao F; Cui JG; Liu HC
Ai Zheng; 2007 Aug; 26(8):820-7. PubMed ID: 17697540
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
17. STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma.
Klein JD; Sano D; Sen M; Myers JN; Grandis JR; Kim S
PLoS One; 2014; 9(1):e81819. PubMed ID: 24404126
[TBL] [Abstract][Full Text] [Related]
18. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
Kandala PK; Srivastava SK
BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
[TBL] [Abstract][Full Text] [Related]
19. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
Sun S; Wu Y; Guo W; Yu F; Kong L; Ren Y; Wang Y; Yao X; Jing C; Zhang C; Liu M; Zhang Y; Zhao M; Li Z; Wu C; Qiao Y; Yang J; Wang X; Zhang L; Li M; Zhou X
Clin Cancer Res; 2018 Jun; 24(11):2665-2677. PubMed ID: 29540490
[No Abstract] [Full Text] [Related]
20. Uniquely modified RNA oligonucleotides targeting STAT3 suppress melanoma growth both in vitro and in vivo.
Yang L; Ma X; Xiao L; Tang M; Weng X; Sun L; Cao Y
Cancer Biol Ther; 2009 Nov; 8(21):2065-72. PubMed ID: 19823036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
